Study of ABBV-438 for multiple myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is relapsed (came back) or refractory (didn't respond) after your last treatment.
- You have at least one measurable sign of the disease, such as a certain level of M-protein in blood (≥0.5 g/dL) or urine (≥200 mg/24h), or abnormal free light chains in blood.
- You have tried 3 or more different treatment regimens, including a proteasome inhibitor, an immunomodulatory drug (like lenalidomide or pomalidomide), and an anti-CD38 therapy (like daratumumab), and you cannot tolerate or access other standard treatments.
- You do not have multiple myeloma that has spread to your brain or spinal cord.
- You have no history of certain lung conditions like idiopathic pulmonary fibrosis or organizing pneumonia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.